Page last updated: 2024-11-12

motilin, nle(13)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

motilin, Nle(13)-: linear analog of motilin; increase gastric motility & pepsin output; synthetic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16143638
CHEMBL ID526863
MeSH IDM0052740

Synonyms (7)

Synonym
CHEMBL526863
motilin, nle(13)-
13-nle-motilin
55524-56-6
motilin (pig), 13-l-norleucine-
motilin, norleucine(13)-
13-norleucine-motilin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The study provides pharmacokinetic data for exogenous synthetic and endogenous natural motilin in man."( Pharmacokinetics of motilin in man.
Bloom, SR; Demling, L; Domschke, S; Domschke, W; Mitznegg, P; Wuensch, E, 1977
)
0.26

Dosage Studied

ExcerptRelevanceReference
" 13-nle-motilin increased intraluminal pressure in the pylorus and duodenum, and dose-response analysis showed the duodenum to be twice as sensitive as the pylorus to the polypeptide."( Effects of 13-nle-motilin on the electrical and mechanical activity of the isolated perfused canine stomach and duodenum.
Demling, L; Domschke, W; Green, WE; Ritchie, HD; Ruppin, H; Wingate, DL; Wünsch, DE, 1976
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID347518Potentiation of electric field stimulated-rabbit gastric antrum contraction at 0.3 uM2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
AID347516Potentiation of electric field stimulated-rabbit gastric antrum contraction at 3 uM2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
AID347505Half life in rabbit gastric antrum native tissue at 0.3 uM2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
AID347519Potentiation of electric field stimulated-rabbit gastric antrum contraction at 0.1 uM2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
AID347517Potentiation of electric field stimulated-rabbit gastric antrum contraction at 1 uM2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (53.85)18.7374
1990's3 (23.08)18.2507
2000's3 (23.08)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.60 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]